Current assets

EX-10.2 3 c49369exv10w2.htm EXHIBIT 10.2 exv10w2
Exhibit 10.2
AMENDMENT NO. 5 TO STOCKHOLDERS AGREEMENT
     THIS AMENDMENT NO. 5 TO STOCKHOLDERS AGREEMENT is entered into effective this 13th day of February, 2009 (this “Amendment No. 5”), by and among Cardiovascular Systems, Inc., a Minnesota Corporation (the “Company”) and the Holders and Investors signatory hereto.
RECITALS
     WHEREAS, this Amendment No. 5 amends the Stockholders Agreement, dated July 19, 2006 (the "Stockholders Agreement”), by and between the Company and the “Holders,” “Investors,” and “Section 5 Holders” set forth on Schedule I thereto, as amended by that certain Amendment No. 1 to Stockholders Agreement, dated October 3, 2006, by and between the Company, ITX International Equity Corp. and the Holders and Investors signatory thereto; that certain Amendment No. 2 to Stockholders Agreement, dated September 19, 2007, by and between the Company, the Series A-1 Convertible Preferred Stockholders and the Holders and Investors signatory thereto; that certain Amendment No. 3 to Stockholders Agreement, dated December 17, 2007, by and between the Company, the Series B Convertible Preferred Stockholders and the Holders and Investors signatory thereto; and that certain Amendment No. 4 to Stockholders Agreement, dated September 12, 2008, by and between the Company, Silicon Valley Bank and the Holders and Investors signatory thereto;
     WHEREAS, the Company filed a Form 10 registration statement with the U.S. Securities Exchange Commission (“SEC”) on October 28, 2008 and such registration statement became effective on December 29, 2008;
     WHEREAS, upon the effectiveness of the registration statement, the Company became subject to the SEC periodic reporting requirements and has a class of equity securities registered under Section 12 of the Securities Exchange Act of 1934, as amended;
     WHEREAS the existence of the Stockholders Agreement triggers certain SEC reporting requirements on behalf of the parties thereto and the parties hereto wish to facilitate the making of any such reports;
     WHEREAS, Holders executing this Amendment No. 5 hold a majority of the Shares subject to the Stockholders Agreement; and
     WHEREAS, Investors executing this Amendment No. 5 hold a majority in interest of the shares of Common Stock issued or issuable to the Investors.
     NOW THEREFORE, in consideration of the mutual covenants and agreements contained in this Amendment No. 5, the sufficiency of which is hereby acknowledged, the parties hereto agree as set forth below:

1


 

1.   Capitalized terms not defined herein shall have the meanings ascribed to them in the Stockholders Agreement.
     2. The following is added as Section 24 to the Stockholders Agreement:
Investors’ Representatives. David L. Martin and Laurence L. Betterley, acting together or individually, are hereby appointed the representatives of the Investors and Holders, with full power to execute and file with the SEC and any stock exchange or similar authority, for and on behalf of the Investors and Holders in any and all capacities, any and all reports required to be filed under Section 13 of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder by such Investors and Holders as a group as a consequence of their being parties to the Stockholders Agreement, including, without limitation, reports on Schedule 13D or Schedule 13G, and any and all amendments to such reports, with all exhibits and any other forms or documents as may be necessary in connection with the filing of such reports with the SEC and any stock exchange or similar authority, granting unto said representatives full power and authority to do and perform any and all acts for and on behalf of the Investors and Holders which may be necessary or desirable to complete, as fully as the Investors and Holders might or could do in person. This appointment shall expire automatically upon the closing of the Company’s merger with Responder Merger Sub, Inc., a wholly-owned subsidiary of Replidyne, Inc. The representatives shall provide Maverick a reasonable opportunity to review and comment upon such Schedule 13D or Schedule 13G and each amendment thereto prior to filing.”
3.   This Amendment No. 5 may be executed in any number of original or facsimile counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Any counterpart or other signature to this Amendment No. 5 that is delivered by facsimile shall be deemed for all purposes as constituting good and valid execution and delivery by such party of this Amendment No. 5.
4.   Except as set forth herein, all other terms and conditions of the Stockholders Agreement remain the same.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

2


 

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
         
  COMPANY

CARDIOVASCULAR SYSTEMS, INC.
 
 
  By:   /s/ Laurence Betterley    
    Name:   Laurence Betterley   
    Title:   Chief Financial Officer   
 

 


 

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
             
    HOLDERS    
 
           
    /s/ Gary M. Petrucci    
         
    Gary M. Petrucci    
 
           
    /s/ Michael J. Kallok    
         
    Michael J. Kallok    
 
           
    GDN HOLDINGS, LLC    
 
           
 
  By:   /s/ Glen D. Nelson    
 
           
 
      Name: Glen D. Nelson    
 
      Title: Member    
 
           
    GEOFFREY O. HARTZLER REV TRUST DTD 1/8/97, AS AMENDED    
 
           
 
  By:   /s/ Geoffrey O. Hartlzer    
 
           
 
      Name: Geoffrey O. Hartzler    
 
      Title: Trustee    
 
           
    /s/ Geoffrey O. Hartlzer    
         
    Geoffrey O. Hartzler    
 
           
    /s/ Roger J. Howe    
         
    Roger J. Howe, Ph. D.    

 


 

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
             
    INVESTORS    
 
           
    EASTON HUNT CAPITAL PARTNERS, L.P.    
 
           
 
  By:   EHC GP, L.P. its General Partner    
 
  By:   EHC GP, Inc., its General Partner    
 
           
 
  By:   /s/ Richard P. Schneider    
 
           
 
      Name: Richard P. Schneider    
 
      Title: Vice President & Secretary    
 
           
    EASTON CAPITAL PARTNERS, LP    
 
           
 
  By:   ECP GP, LLC    
 
  By:   ECP GP, Inc., its Manager    
 
           
 
  By:   /s/ Richard P. Schneider    
 
           
 
      Name: Richard P. Schneider    
 
      Title: Vice President & Secretary    

 


 

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
             
    INVESTORS    
 
           
    MAVERICK FUND, L.D.C.    
 
           
 
  By:   Maverick Capital, Ltd.    
 
      Its Investment Advisor    
 
           
 
  By:   /s/ John T. McCafferty    
 
           
 
      Name: John T. McCafferty    
 
      Title: Limited Partner and General Counsel    
 
           
    MAVERICK FUND USA, LTD.    
 
           
 
  By:   Maverick Capital, Ltd.    
 
      Its Investment Advisor    
 
           
 
  By:   /s/ John T. McCafferty    
 
           
 
      Name: John T. McCafferty    
 
      Title: Limited Partner and General Counsel    
 
           
    MAVERICK FUND II, LTD.    
 
           
 
  By:   Maverick Capital, Ltd.    
 
      Its Investment Advisor    
 
           
 
  By:   /s/ John T. McCafferty    
 
           
 
      Name: John T. McCafferty    
 
      Title: Limited Partner and General Counsel    

 


 

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
         
  INVESTORS

MITSUI & CO. VENTURE PARTNERS II, L.P.
 
 
  By:   Mitsui & Co. Venture Partners, Inc.    
    Its General Partner   
       
 
     
  By:   /s/ Taro Inaba    
    Name:   Taro Inaba   
    Title:   President & CEO   

 


 

         
     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
         
  INVESTORS

ITX INTERNATIONAL EQUITY CORP.
 
 
  By:   /s/ Takehito Jimbo    
    Name:   Takehito Jimbo   
    Title:   President & CEO   

 


 

         
     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 5 to Stockholders Agreement effective the date first written above.
         
  INVESTORS

WHITEBOX HEDGED HIGH YIELD PARTNERS, LP
 
 
  By:   /s/ Jonathan Wood    
    Name:   Jonathan Wood   
    Title:   Director & COO   
 
  WHITEBOX COMBINED PARTNERS, LP
 
 
  By:   /s/ Jonathan Wood    
    Name:   Jonathan Wood   
    Title:   Director & COO